Last reviewed · How we verify

Cocktail of CYP450 substrates

Galapagos NV · Phase 1 active Small molecule Quality 25/100

Cocktail of CYP450 substrates is a Small molecule drug developed by Galapagos NV. It is currently in Phase 1 development.

At a glance

Generic nameCocktail of CYP450 substrates
SponsorGalapagos NV
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cocktail of CYP450 substrates

What is Cocktail of CYP450 substrates?

Cocktail of CYP450 substrates is a Small molecule drug developed by Galapagos NV.

Who makes Cocktail of CYP450 substrates?

Cocktail of CYP450 substrates is developed by Galapagos NV (see full Galapagos NV pipeline at /company/galapagos-nv).

What development phase is Cocktail of CYP450 substrates in?

Cocktail of CYP450 substrates is in Phase 1.

What are the side effects of Cocktail of CYP450 substrates?

Common side effects of Cocktail of CYP450 substrates include International normalised ratio increased, Nausea, Headache, Abdominal pain, Constipation, Vomiting.

Related